| Date | Title | Description | |
|---|---|---|---|
| 03 Jan 2022 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 27 December 2021 and 31 December 2021 | Download |
| 28 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 20 December 2021 and 24 December 2021 | Download |
| 20 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 13 December 2021 and 17 December 2021 | Download |
| 17 Dec 2021 | On business and financial situation | ROVI reports that the CHMP has issued a positive opinion on Okedi® for the treatment for schizophrenia | Download |
| 13 Dec 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 6 December 2021 and 10 December 2021 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 31 Jan 2020 | R&D: new licenses, patents and registered trademarks | The Company informs about the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union | Download |
| 08 Jan 2020 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2019 | Download |
| 20 Dec 2019 | Composition of the board of directors | The Company informs about the composition of its Board of Directors and its Audit and Appointments and Remuneration Committees. | Download |
| 24 Nov 2019 | Strategic plans, profit forecasts and presentations | The Company releases the presentation related to its strategy update because of the 2019 Investor Day. | Download |
| 07 Nov 2019 | Information on P&L | ROVI releases the press release related to the first nine months 2019 financial results | Download |